Skip to content

Shares (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
895.9M-0.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
28.7M-6.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
24.7M+75.9%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
137.6M-3.9%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
97.5M+21.7%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
129.4M+2.6%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's shares (diluted)?
MoonLake Immunotherapeutics (MLTX) reported shares (diluted) of 71.3M in Q1 2026.
How has MoonLake Immunotherapeutics's shares (diluted) changed year-over-year?
MoonLake Immunotherapeutics's shares (diluted) increased by 12.7% year-over-year, from 63.2M to 71.3M.
What is the long-term trend for MoonLake Immunotherapeutics's shares (diluted)?
Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's shares (diluted) has grown at a 22.9% compound annual growth rate (CAGR), from 111.5M to 254.4M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.